{
    "clinical_study": {
        "@rank": "66963", 
        "arm_group": {
            "arm_group_label": "Aleglitazar", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, fixed-sequence, three-period, single group study will evaluate the effects\n      of rifampicin on the pharmacokinetics of aleglitazar in healthy volunteers. Volunteers will\n      receive single doses of aleglitazar in all three periods and single doses of rifampicin in\n      periods 1 and 2, and multiple doses in period 3. The anticipated time on study treatment is\n      up to 14 weeks."
        }, 
        "brief_title": "A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers, aged 18 to 55 years inclusive at the time of screening\n\n          -  Body mass index (BMI) between 18.0 and 35.0 kg/m2 inclusive\n\n          -  Females must be surgically sterile or use two acceptable methods of contraception\n\n          -  Non-smoker or currently smoking less than five cigarettes/day and willing to abstain\n             from smoking during the study\n\n        Exclusion Criteria:\n\n          -  Any clinically relevant abnormal laboratory test results at screening or on Day -1 of\n             all periods, as judged by the Investigator\n\n          -  A history of clinically significant disorders (e.g., gastro-intestinal,\n             cardiovascular, hepatic)\n\n          -  Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C\n\n          -  An average alcohol intake of more than 14 units per week\n\n          -  Volunteers diagnosed, or suspected of having porphyria, and subjects with first\n             degree relatives diagnosed, or suspected of having porphyria\n\n          -  Diagnosis of Gilberts Syndrome\n\n          -  A positive screen for drugs of abuse at screening or on admission to the clinical\n             unit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679639", 
            "org_study_id": "BP25561", 
            "secondary_id": "2012-002274-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aleglitazar", 
                "description": "Single dose of aleglitazar in Periods 1, 2, 3", 
                "intervention_name": "aleglitazar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aleglitazar", 
                "description": "Single dose in Periods 1 and 2; multiple doses in Period 3", 
                "intervention_name": "rifampicin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rifampin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "zip": "M13 9WL"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Fixed-sequence, Three-period, Single Group Study to Investigate the Effects of Rifampicin as an OATP1B1 Inhibitor and a CYP2C8 Inducer on the Pharmacokinetics of Aleglitazar in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics: Area under the plasma concentration time curve", 
            "safety_issue": "No", 
            "time_frame": "Period 1 and 2: Predose and days 1 to 5; Period 3: Days 5 to 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679639"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "14 weeks"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}